Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide-March 2024-www.financetom.com

Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide

Mar 7, 2024 8:15 AM

10:46 AM EST, 03/07/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ), (ARCH.V) on Thursday said that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

There are three hospital sites in Turkey actively screening cardiac surgery patients for this trial. There are three additional hospital sites in Turkey pending activation into the trial.

The Arch Biopartners ( ACHFF ) team is currently working with hospital sites in Canada to prepare for their participation in this Phase II trial.

Price: 1.59, Change: +0.03, Percent Change: +1.92

Previous page： Ooma Fiscal Q1 Non-GAAP EPS Decreases, Revenue Rises; Q2, Fiscal 2025 Outlook Issued -- Shares Jump After Hours Next page： Tourmaline OIl Raising $250 Million in an Issue of Senior Unsecured Notes.

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Ooma Fiscal Q1 Non-GAAP EPS Decreases, Revenue Rises; Q2, Fiscal 2025 Outlook Issued -- Shares Jump After Hours

May 28, 2024

05:03 PM EDT, 05/28/2024 (MT Newswires) -- Ooma ( OOMA ) reported fiscal Q1 non-GAAP earnings late Tuesday of $0.14 per diluted share, down from $0.16 a year earlier. Analysts polled by Capital IQ expected $0.11. Revenue for the quarter ended April 30 was $62.5 million, up from $56.9 million a year earlier. Analysts surveyed by Capital IQ expected $61.8...

Tourmaline OIl Raising $250 Million in an Issue of Senior Unsecured Notes.

May 28, 2024

05:03 PM EDT, 05/28/2024 (MT Newswires) -- Tourmaline Oil (TOU.TO) on Tuesday said it is raising $250 million in an issue of senior unsecured notes due May 30, 2027. The Western Canadian oil and gas producer said the notes carry an interest rate of 4.856% and will be issued at par. Tourmaline continues its strategy of diversifying its sources of...

Avidxchange Holdings Insider Sold Shares Worth $313,289, According to a Recent SEC Filing

May 28, 2024

05:02 PM EDT, 05/28/2024 (MT Newswires) -- Todd Alan Cunningham, Chief People Officer, Senior Vice President, on May 23, 2024, sold 28,424 shares in Avidxchange Holdings ( AVDX ) for $313,289. Following the Form 4 filing with the SEC, Cunningham has control over a total of 336,017 shares of the company, with 336,017 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1858257/000095017024065321/xslF345X03/ownership.xml ...

Salesforce Insider Sold Shares Worth $4,075,924, According to a Recent SEC Filing

May 28, 2024

05:01 PM EDT, 05/28/2024 (MT Newswires) -- Marc Benioff, Director, Chair and CEO, on May 24, 2024, sold 15,000 shares in Salesforce ( CRM ) for $4,075,924. Following the Form 4 filing with the SEC, Benioff has control over a total of 22,452,327 shares of the company, with 12,452,327 shares held directly and 10,000,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760224016709/xslF345X03/form4.xml ...